These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 3569414)
1. Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Deutch AY; Tam SY; Freeman AS; Bowers MB; Roth RH Eur J Pharmacol; 1987 Feb; 134(3):257-64. PubMed ID: 3569414 [TBL] [Abstract][Full Text] [Related]
2. Neurochemical studies on central dopamine neurons--regional characterization of dopamine turnover. Hallman H; Jonsson G Med Biol; 1984; 62(3):198-209. PubMed ID: 6492900 [TBL] [Abstract][Full Text] [Related]
3. Effects of 6-hydroxydopamine lesions of the prefrontal cortex on tyrosine hydroxylase activity in mesolimbic and nigrostriatal dopamine systems. Rosin DL; Clark WA; Goldstein M; Roth RH; Deutch AY Neuroscience; 1992 Jun; 48(4):831-9. PubMed ID: 1352864 [TBL] [Abstract][Full Text] [Related]
4. Effects of acute GR38032F (odansetron), a 5-HT3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons. Koulu M; Sjöholm B; Lappalainen J; Virtanen R Eur J Pharmacol; 1989 Oct; 169(2-3):321-4. PubMed ID: 2530097 [TBL] [Abstract][Full Text] [Related]
5. Opiate actions on mesocortical dopamine metabolism in the rat. Kim HS; Iyengar S; Wood PL Life Sci; 1986 Nov; 39(21):2033-6. PubMed ID: 3784768 [TBL] [Abstract][Full Text] [Related]
6. Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study. Lategan AJ; Marien MR; Colpaert FC Life Sci; 1992; 50(14):995-9. PubMed ID: 1372673 [TBL] [Abstract][Full Text] [Related]
8. Serotoninergic modulation of mesolimbic and frontal cortical dopamine neurons. Waldmeier PC Experientia; 1980 Sep; 36(9):1092-4. PubMed ID: 6448165 [TBL] [Abstract][Full Text] [Related]
9. Effects of acute administration of SCH 23390 on dopamine and serotonin turnover in major dopaminergic areas and mesencephalic raphe nuclei--comparison with ritanserin. Lappalainen J; Hietala J; Koulu M; Sjöholm B; Syvälahti E Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(6):861-72. PubMed ID: 1722342 [TBL] [Abstract][Full Text] [Related]
10. Phencyclidine binding sites in the nucleus accumbens and phencyclidine-induced hyperactivity are decreased following lesions of the mesolimbic dopamine system. French ED; Pilapil C; Quirion R Eur J Pharmacol; 1985 Oct; 116(1-2):1-9. PubMed ID: 2996909 [TBL] [Abstract][Full Text] [Related]
11. Footshock and conditioned stress increase 3,4-dihydroxyphenylacetic acid (DOPAC) in the ventral tegmental area but not substantia nigra. Deutch AY; Tam SY; Roth RH Brain Res; 1985 Apr; 333(1):143-6. PubMed ID: 3995282 [TBL] [Abstract][Full Text] [Related]
12. Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release. Broderick PA; Piercey MF J Neural Transm (Vienna); 1998; 105(6-7):749-67. PubMed ID: 9826116 [TBL] [Abstract][Full Text] [Related]
13. Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain. Jiang DH; Reches A; Wagner HR; Fahn S Neuropharmacology; 1984 Mar; 23(3):295-301. PubMed ID: 6539428 [TBL] [Abstract][Full Text] [Related]
14. Activation of dopamine synthesis in mesolimbic dopamine neurons by immobilization stress in the rat. Watanabe H Neuropharmacology; 1984 Nov; 23(11):1335-8. PubMed ID: 6441893 [TBL] [Abstract][Full Text] [Related]
15. The effect of phencyclidine on dopamine synthesis and metabolic in rat striatum. Doherty JD; Simonovic M; So R; Meltzer HY Eur J Pharmacol; 1980 Jul; 65(2-3):139-49. PubMed ID: 7398783 [TBL] [Abstract][Full Text] [Related]
16. Turnover of acid dopamine metabolites in striatal and mesolimbic tissue of the rat brain. Westerink BH; Korf J Eur J Pharmacol; 1976 Jun; 37(2):249-55. PubMed ID: 954808 [TBL] [Abstract][Full Text] [Related]
17. Differential effects of chronic nicotine administration on dopaminergic receptor binding sites in rat nigrostriatal and mesolimbic regions. Fung YK; Lau YS Gen Pharmacol; 1991; 22(1):117-9. PubMed ID: 2050279 [TBL] [Abstract][Full Text] [Related]
18. Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. Ossowska K; Smiałowska M; Kuter K; Wierońska J; Zieba B; Wardas J; Nowak P; Dabrowska J; Bortel A; Biedka I; Schulze G; Rommelspacher H Neuroscience; 2006 Sep; 141(4):2155-65. PubMed ID: 16797138 [TBL] [Abstract][Full Text] [Related]
19. Chronic D-amphetamine and phencyclidine: effects on dopamine agonist and antagonist binding sites in the extrapyramidal and mesolimbic systems. Robertson HA Brain Res; 1983 May; 267(1):179-82. PubMed ID: 6860944 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo. Rao TS; Kim HS; Lehmann J; Martin LL; Wood PL Life Sci; 1989; 45(12):1065-72. PubMed ID: 2796597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]